TherapeuticsMD (NASDAQ:TXMD) Trading 2.4% Higher – Should You Buy?
by Amy Steele · The Cerbat GemTherapeuticsMD, Inc. (NASDAQ:TXMD – Get Free Report) shot up 2.4% during trading on Friday . The stock traded as high as $1.77 and last traded at $1.74. 34,380 shares changed hands during mid-day trading, a decline of 36% from the average session volume of 53,553 shares. The stock had previously closed at $1.70.
Analysts Set New Price Targets
Separately, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of TherapeuticsMD in a research report on Monday. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, TherapeuticsMD currently has a consensus rating of “Sell”.
Read Our Latest Report on TXMD
TherapeuticsMD Stock Up 2.4%
The business has a 50-day simple moving average of $1.54 and a two-hundred day simple moving average of $1.26. The company has a market cap of $20.13 million, a price-to-earnings ratio of -174.00 and a beta of 0.41.
TherapeuticsMD (NASDAQ:TXMD – Get Free Report) last issued its quarterly earnings data on Wednesday, November 12th. The company reported $0.01 EPS for the quarter. TherapeuticsMD had a return on equity of 0.27% and a net margin of 10.80%.The business had revenue of $0.78 million for the quarter.
Institutional Trading of TherapeuticsMD
An institutional investor recently raised its position in TherapeuticsMD stock. Citadel Advisors LLC raised its holdings in TherapeuticsMD, Inc. (NASDAQ:TXMD – Free Report) by 125.5% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 34,273 shares of the company’s stock after buying an additional 19,073 shares during the quarter. Citadel Advisors LLC owned 0.30% of TherapeuticsMD worth $36,000 at the end of the most recent quarter. Institutional investors own 30.74% of the company’s stock.
About TherapeuticsMD
TherapeuticsMD, Inc (NASDAQ:TXMD) is a women’s healthcare company dedicated to the development and commercialization of hormone therapy and contraceptive products. The company’s primary focus lies in addressing unmet needs in menopause management and birth control by offering innovative, non-estrogen alternatives designed to improve patient convenience and adherence. TherapeuticsMD operates in the United States, serving women through a specialty care distribution network that includes physician practices, clinics and pharmacies.
Among its flagship products is IMVEXXY, an FDA-approved low-dose vaginal estradiol insert indicated for the treatment of moderate to severe dyspareunia due to menopause.